Could a new drug offer hope for Treatment-Resistant depression?
NCT ID NCT06009003
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This program provides access to esmethadone (REL-1017), an experimental drug, for people with serious depression who have not responded to standard treatments and cannot join other clinical trials. The goal is to offer a potential treatment option when no satisfactory alternative exists. Participants receive esmethadone tablets under the supervision of their treating physician.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- esmethadone (REL-1017) tablet
- What this could lead to
- If successful, this program could provide a treatment option for people with severe depression who have exhausted standard therapies.
- What could go wrong
- This is an expanded access program, not a controlled trial, so its effectiveness and safety are not systematically evaluated. Esmethadone may have side effects and is not a proven cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may hold clues to depression – a new device listens in
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Could the sound of your voice reveal depression?
- Can a structured care pathway ease teen depression?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can a nasal spray break through tough depression?